Antibiotic tissue concentrations revisited in lungs

Critical Care Medicine

Volumn 31, Issue 8, 2003, Pages 2242-2243

  Bergogne Berezin, Eugenie ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Cefepime; Continuous infusion; Epithelial lining fluid; Time dependence; Tissue concentrations

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CEFEPIME; CEFTAZIDIME; CEPHALOSPORIN; CEPHALOSPORIN DERIVATIVE;

ANTIMICROBIAL ACTIVITY; AREA UNDER THE CURVE; DOSE RESPONSE; DRUG TISSUE LEVEL; EDITORIAL; HUMAN; INFECTION; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL;

CEPHALOSPORINS; HUMANS; INFUSIONS, INTRAVENOUS; LUNG; PNEUMONIA, BACTERIAL;

EID: 0041441173     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000069735.58871.26     Document Type: Editorial

References (15)

1. Nix DE, Goodwin SD, Peloquin CA, et al: Antibiotic tissue penetration and its relevance: Models of tissue penetration and their meaning. Antimicrob Agents Chemother 1991; 35:1947-1952
2. Carbon C: Significance of tissue levels for prediction of antibiotic efficacy and determination of dosage. Eur J Clin Microbiol Infect Dis 1990; 9:510-516
3. Barza M: Tissue-directed antibiotic therapy: Antibiotic dynamics in cells and tissue. Challenges to antibiotic activity in tissue. Clin Infect Dis 1994; 19:910-915
4. Honeybourne D, Baldwin DR: The site concentrations of antimicrobial agents in the lung. J Antimicrob Chemother 1992; 30:249-260
5. Bergogne-Bérézin E: New concepts in the pulmonary disposition of antibiotics. Pulm Pharmacol 1995; 8:65-81
6. Craig WA: Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing in mice and men. Clin Infect Dis 1998; 26:1-12
7. Leggett JE, Fantin B, Ebert S, et al: Comparative antibiotic dose-effects relations at several dosing intervals in murine pneumonitis and thigh-infection models. J Infect Dis 1989; 159:281-292
8. Craig WA: Interrelationships between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad spectrum-cephalosporins. Diagn Microbiol Infect Dis 1995; 22:89-96
9. Roosendaal R, Bakker-Woundenberg IAJM, van den Berg JC et al: Therapeutic efficacy of continuous versus intermittent administration of ceftazidime in an experimental K. pneumoniae pneumonia in rats. J Infect Dis 1985; 152:281-292
10. Nicolau DP, Nightindale CH, Banevicius MA, et al: Serum bactericidal activity of ceftazidime: Continuous infusion versus intermittent injections. Antimicrob Agents Chemother 1996; 40:61-64
11. Vinks A, Brimicombe RW, Heijerman HGM: Continuous infusion of ceftazidime in adult cystic fibrosis patients during continuous infusion and ambulatory treatment at home: Clinical outcome, microbiology and pharmacokinetics. J Antimicrob Chemother 1997; 40:125-133
12. Houlihan HH, Mercier RC, Mc Kinnon PS, et al: Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with Gram negative infection. Paper presented at: 37th ICAAC, 1997, Toronto, Abstract A-42
13. Benko AS, Cappelletty DM, Kruse JA, et al: Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected Gram-negative infections. Antimicrob Agents Chemother 1996; 40:691-695
14. Boselli E, Breilh D, Duflo F, et al: Steady-state plasma and intrapulmonary concentrations of cefepime administered in continuous infusion in critically ill patients with severe nosocomial pneumonia. Crit Care Med 2003; 31:2102-2106
15. Sanders CC: Cefepime: The next generation? Clin Infect Dis 1993; 17:369-379